Ever since its outbreak, Corona Virus Disease 2019 (COVID-19) caused by SARS-CoV-2
has affected more than 26 million individuals in more than 200 countries. Although the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the rapidly spreading pandemic COVID-19 in the world. As an effective therapeutic strategy …

Background and objective COVID-19 neurological manifestations have been progressively
recognized. Among available MRI techniques, diffusion weighted imaging (DWI) shows …

Background COVID‐19 patients, especially the patients requiring hospitalisation, have a
high risk of several complications such as opportunistic bacterial and fungal infections …

Background. SARS‐CoV‐2 is responsible for COVID‐19, a clinically heterogeneous
disease, ranging from being completely asymptomatic to life‐threating manifestations. An …

Background Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of
their ability in restraining immune response, yet the corroboration regarding their advantage …

It is of interest to document the Molecular Dynamics Simulation and docking analysis of NF-
κB target with sulindac sodium in combating COVID-19 for further consideration. Sulindac is …

Coronaviruses have lipid envelopes required for their activity. The fact that coronavirus
infection provokes the formation of cubic membranes (CM)(denoted also as convoluted …

Background Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-
2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers …

Since the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has
spread as a new strain of coronavirus disease (COVID‐19) and progressed as a global …